Dimethyl fumarate (Tecfidera) vs Diroximel fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline

Dimethyl fumarate (Tecfidera)

Marketed by Biogen

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT00451451 · Phase 3 · completed

This was a large (n=1417), randomized, double-blind, placebo-controlled Phase 3 trial with a hard clinical primary endpoint (annualized relapse rate, independently adjudicated). Both BG00012 dosing arms showed clearly separated confidence intervals from placebo on this primary endpoint (0.224 and 0.198 relapses/year vs 0.401 for placebo), indicating the drug met its primary comparison in the favorable direction, satisfying all the elements of well-designed, positive Phase 3 evidence.

Reported efficacy

Annualized Relapse Rate (2 years): Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo. (met)

Result source: NCT00451451

Diroximel fumarate · Vumerity

Marketed by Biogen and partners

Approved in Multiple Sclerosissmall molecule (fumarate prodrug)
Weak signal

NCT05083923 · Phase 3 · completed

The study was a single-group, open-label trial with 136 participants enrolled and no placebo or active comparator. Its primary outcomes were safety measures rather than a comparative clinical efficacy endpoint, so there was no formal primary treatment comparison to meet or miss; the reported safety findings are descriptive only.

Next expected readout: July 2034 · NCT07483632 (registry estimate)

Reported efficacy

Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B (End of treatment (up to Week 6) for both Parts A and B): Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. (met)

Result source: NCT03093324

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDimethyl fumarate (Tecfidera)Diroximel fumarate
Annualised relapse rate0.2 vs 0.4−0.2 vs placebo240 mg twice daily · wk 104 · n 359NCT00451451
5 other results
  • 0.2 vs 0.4 240 mg 3 times daily · wk 104 · n 345 · Phase 3 · primary NCT00451451
  • 0.2 vs 0.4 240 mg BID · wk 104 · n 410 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.4 240 mg TID · wk 104 · n 416 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.5 wk 96 · n 78 · Phase 3 · secondary NCT02283853
  • 0.3 vs 0.6 wk 48 · n 78 · Phase 3 · secondary NCT02283853
—Trial running · NCT07483632
Free of 3-month confirmed disability progression (%)—Not reported—Trial running · NCT07483632
New or enlarging T2 lesions—Not reported—Trial running · NCT07483632

Annualised relapse rate

Dimethyl fumarate (Tecfidera)
0.2 vs 0.4−0.2 vs placebo240 mg twice daily · wk 104 · n 359NCT00451451
5 other results
  • 0.2 vs 0.4 240 mg 3 times daily · wk 104 · n 345 · Phase 3 · primary NCT00451451
  • 0.2 vs 0.4 240 mg BID · wk 104 · n 410 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.4 240 mg TID · wk 104 · n 416 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.5 wk 96 · n 78 · Phase 3 · secondary NCT02283853
  • 0.3 vs 0.6 wk 48 · n 78 · Phase 3 · secondary NCT02283853
Diroximel fumarate
—Trial running · NCT07483632

Free of 3-month confirmed disability progression (%)

Dimethyl fumarate (Tecfidera)
—Not reported
Diroximel fumarate
—Trial running · NCT07483632

New or enlarging T2 lesions

Dimethyl fumarate (Tecfidera)
—Not reported
Diroximel fumarate
—Trial running · NCT07483632
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Dimethyl fumarate (Tecfidera): 6 of 6 rows · Diroximel fumarate: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDimethyl fumarate (Tecfidera)Diroximel fumarate
Annualized Relapse
event rate · per year
No placebo or comparator arm
0.141 per yeara,b,c
NCT02283853 · Phase 3 · registry result, not featured evidence
0.14 per year @ 96wkd,a,b,c
NCT02634307 · Phase 3 · monotherapy
show 2 more doses
0.11 per year @ 96wk
NCT02634307 · Phase 3 · monotherapy
0.13 per year @ 96wk
NCT02634307 · Phase 3 · monotherapy
EDSS
absolute change · score
No placebo or comparator arm
-0.11 score @ 336wka,b,e
NCT02283853 · Phase 3 · registry result, not featured evidence
0.07 score @ 96wkd,a,b,e
NCT02634307 · Phase 3 · monotherapy
show 2 more doses
-0.01 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
0.03 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
Dropout rate
20.9%240 mg 3 times dailyf
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 13 more results
20.9%240 mg twice daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
23.1%240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
23.2%240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
55.8%240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
56.8%240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
14.8%
NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy
21.5%Part 1: BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—Part 2: BG00012/ BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—
NCT02555215 · Phase 3 · registry result, not featured evidence
27.5%
NCT02525874 · Phase 3 · registry result, not featured evidence
9.1%
NCT02410200 · Phase 2 · registry result, not featured evidence
—Add-on Therapy Period: GA and BG00
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
—Add-on Therapy Period: IFNß and BG
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
9.6%Cohort 1: Japanese Participantsg
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
20%Cohort 2: Chinese Participants
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
21.1%De Novo
NCT02634307 · Phase 3 · monotherapy
29.7%Rollover: ALKS 8700
NCT02634307 · Phase 3 · monotherapy
27.1%Rollover: DMF
NCT02634307 · Phase 3 · monotherapy
3.5%
NCT03093324 · Phase 3 · monotherapy
Discontinued due to AEs
7.5%240 mg 3 times dailyf
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 13 more results
5.8%240 mg twice daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
8.7%240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
9.8%240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
13%240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
14.3%240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
10.1%
NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy
6.3%Part 1: BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—Part 2: BG00012/ BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—
NCT02555215 · Phase 3 · registry result, not featured evidence
7.8%
NCT02525874 · Phase 3 · registry result, not featured evidence
9.1%
NCT02410200 · Phase 2 · registry result, not featured evidence
—Add-on Therapy Period: GA and BG00
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
—Add-on Therapy Period: IFNß and BG
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
3.8%Cohort 1: Japanese Participantsg
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
0%Cohort 2: Chinese Participants
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
8.4%De Novo
NCT02634307 · Phase 3 · monotherapy
10%Rollover: ALKS 8700
NCT02634307 · Phase 3 · monotherapy
6.2%Rollover: DMF
NCT02634307 · Phase 3 · monotherapy
1.6%
NCT03093324 · Phase 3 · monotherapy
Serious AEs
15.7%240 mg 3 times dailyf
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 13 more results
17%240 mg twice daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
15.6%240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
18%240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
32.1%240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
31.3%240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
3%
NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy
23.1%Part 1: BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
14%Part 2: BG00012/ BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
10%
NCT02555215 · Phase 3 · registry result, not featured evidence
11.9%
NCT02525874 · Phase 3 · registry result, not featured evidence
22.7%
NCT02410200 · Phase 2 · registry result, not featured evidence
2.1%Add-on Therapy Period: GA and BG00
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
3.5%Add-on Therapy Period: IFNß and BG
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
11.5%Cohort 1: Japanese Participantsg
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
12%Cohort 2: Chinese Participants
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
11.6%De Novo
NCT02634307 · Phase 3 · monotherapy
12.1%Rollover: ALKS 8700
NCT02634307 · Phase 3 · monotherapy
11.1%Rollover: DMF
NCT02634307 · Phase 3 · monotherapy
1.6%
NCT03093324 · Phase 3 · monotherapy
Most frequent reported AEs
240 mg 3 times dailyf
flushing 24.1% (placebo 3.6%)
multiple sclerosis relapse 23.5% (placebo 40.5%)
nasopharyngitis 18.3% (placebo 16%)
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 12 more results
240 mg twice daily
flushing 30.6% (placebo 3.6%)
multiple sclerosis relapse 29% (placebo 40.5%)
nasopharyngitis 17.3% (placebo 16%)
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
240 mg TID
flushing 31.7% (placebo 4.9%)
nasopharyngitis 26.2% (placebo 24.8%)
multiple sclerosis relapse 25.7% (placebo 44.4%)
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
240 mg BID
flushing 37.3% (placebo 4.9%)
multiple sclerosis relapse 26.6% (placebo 44.4%)
nasopharyngitis 26.3% (placebo 24.8%)
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
240 mg twice daily
multiple sclerosis relapse 37.3%
nasopharyngitis 25.3%
urinary tract infection 22.6%
NCT00835770 · Phase 3 · monotherapy
240 mg three times daily
multiple sclerosis relapse 38.6%
nasopharyngitis 26%
flushing 19%
NCT00835770 · Phase 3 · monotherapy
abdominal pain 41%
flushing 38.5%
multiple sclerosis relapse 29.5%
NCT02283853 · Phase 3 · registry result, not featured evidence
multiple sclerosis relapse 26.3%
headache 22.8%
covid-19 19.3%
NCT02283853 · Phase 3 · registry result, not featured evidence
flushing 25%
multiple sclerosis relapse 20%
abdominal pain 15%
NCT02555215 · Phase 3 · registry result, not featured evidence
flushing 45.9%
multiple sclerosis relapse 18.8%
nasopharyngitis 15.1%
NCT02525874 · Phase 3 · registry result, not featured evidence
flushing 45.5%
multiple sclerosis relapse 31.8%
abdominal pain 27.3%
NCT02410200 · Phase 2 · registry result, not featured evidence
flushing 53.2%
alanine aminotransferase increased 14.9%
diarrhoea 14.9%
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
flushing 42.1%
diarrhoea 31.6%
abdominal pain 21.1%
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
g
diarrhoea 36.5%
flushing 32.7%
nasopharyngitis 21.2%
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
upper respiratory tract infection 36%
flushing 18%
lymphocyte count decreased 16%
NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
flushing 38.1%
multiple sclerosis relapse 15.7%
nasopharyngitis 14.5%
NCT02634307 · Phase 3 · monotherapy
multiple sclerosis relapse 19.7%
upper respiratory tract infection 17.6%
lymphopenia 14.6%
NCT02634307 · Phase 3 · monotherapy
multiple sclerosis relapse 19.6%
lymphopenia 16.9%
upper respiratory tract infection 15.6%
NCT02634307 · Phase 3 · monotherapy
flushing 32.8%
diarrhoea 15.4%
nausea 14.6%
NCT03093324 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 336 weeks versus 96 weeks.
  6. fPopulation comparability has not been reviewed for 10 of these studies.
  7. gPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dimethyl fumarate (Tecfidera)

Annualized Relapse 0.224 vs 0.401 placebo per year @ 104wk240 mg twice daily
event rate · per year
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
0.198 vs 0.401 placebo per year @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.172 vs 0.364 placebo per year @ 104wk240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.189 vs 0.364 placebo per year @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.324 vs 0.564 Interferon β-1a per year @ 48wk
NCT02283853 · Phase 3 · registry result, not featured evidence
0.24 vs 0.528 Interferon β-1a per year @ 96wk
NCT02283853 · Phase 3 · registry result, not featured evidence
New or Newly Enlarging T2 Lesion 5.1 vs 17.4 placebo count @ 104wk240 mg twice daily
event count · count
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
4.7 vs 17.4 placebo count @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
2.6 vs 17 placebo count @ 104wk240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
4.4 vs 17 placebo count @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
10 vs 11.9 Interferon β-1a count @ 24wk
NCT02283853 · Phase 3 · registry result, not featured evidence
19.4 vs 32.1 Interferon β-1a count @ 96wk
NCT02283853 · Phase 3 · registry result, not featured evidence
New T1 Hypointense Lesion 3 vs 7 placebo count @ 104wk240 mg twice daily
event count · count
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
2.4 vs 7 placebo count @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Relapsed Subjects 0.291% (n=359) vs 0.41% (n=363) placebo @ 104wk240 mg twice daily
event count · % of participants
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.241% (n=345) vs 0.41% (n=363) placebo @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Disability Progression 0.128% (n=359) vs 0.169% (n=363) placebo @ 104wk240 mg twice daily
event count · % of participants
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 3 more results
0.13% (n=345) vs 0.169% (n=363) placebo @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.164% (n=409) vs 0.271% (n=408) placebo @ 104wk240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.177% (n=416) vs 0.271% (n=408) placebo @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Relapse Proportion 0.27% (n=410) vs 0.461% (n=408) placebo @ 104wk240 mg BID
responder rate · % of participants
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.26% (n=416) vs 0.461% (n=408) placebo @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
MRI Gadolinium Lesion-Free 93.4% (n=152) vs 62.4% (n=165) placebo @ 104wk240 mg BID
event count · % of participants
0 lesions
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 · converted to % from 142 Number of subjects as posted
show 1 more result
85.5% (n=152) vs 62.4% (n=165) placebo @ 104wk*240 mg TID
0 lesions
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 · converted to % from 130 Number of subjects as posted
Relapse Occurrence 40% (n=501) @ 384wk240 mg twice daily
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00835770 · Phase 3 · monotherapy
show 5 more results
41% (n=502) @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
34% (n=249) @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
36% (n=248) @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
31% (n=118) @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
31% (n=118) @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
Annualized Relapse 0.159 per year @ 384wk240 mg twice daily
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00835770 · Phase 3 · monotherapy
show 5 more results
0.179 per year @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.2 per year @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.199 per year @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.184 per year @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.212 per year @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
EDSS 0.28 score @ 384wk240 mg twice daily
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT00835770 · Phase 3 · monotherapy
show 5 more results
0.26 score @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.37 score @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.53 score @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.39 score @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.49 score @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
SF-36 Physical Functioning 0.73 score @ 384wk240 mg twice daily
absolute change · score
Extension (open-label)
No placebo or comparator arm
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
show 5 more results
-4.79 score @ 384wk240 mg three times daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-7.37 score @ 384wk240 mg twice daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-6.89 score @ 384wk240 mg three times daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-6.19 score @ 384wk240 mg twice daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-6.25 score @ 384wk240 mg three times daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
SF-36 - Role Physical 3.2 score @ 384wk240 mg twice daily
absolute change · score
Extension (open-label)
No placebo or comparator arm
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
show 5 more results
-2.75 score @ 384wk240 mg three times daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-10 score @ 384wk240 mg twice daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-8.24 score @ 384wk240 mg three times daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-12.21 score @ 384wk240 mg twice daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-1.04 score @ 384wk240 mg three times daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy

+ 17 further endpoints in the CSV export.

Diroximel fumarate

Relapse 17.66% (n=593) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 2 more results
16.66% (n=239) @ 96wk
NCT02634307 · Phase 3 · monotherapy
18.3% (n=225) @ 96wk
NCT02634307 · Phase 3 · monotherapy
T25FW -0.05 seconds @ 12wk
absolute change · seconds
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 23 more results
0 seconds @ 12wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 12wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 24wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 36wk
NCT02634307 · Phase 3 · monotherapy
-0.1 seconds @ 36wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 36wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 48wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 60wk
NCT02634307 · Phase 3 · monotherapy
-0.09 seconds @ 60wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 60wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 72wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 84wk
NCT02634307 · Phase 3 · monotherapy
-0.075 seconds @ 84wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 84wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.05 seconds @ 96wk
NCT02634307 · Phase 3 · monotherapy
0 seconds @ 96wk
NCT02634307 · Phase 3 · monotherapy
EQ-5D VAS 1 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 11 more results
-1.6 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-1.6 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
0.3 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-2.8 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-1.9 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
1.3 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-2.8 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-2.1 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
0.6 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-4.2 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-3.7 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
EQ-5D Index -0.002 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy
show 11 more results
-0.018 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.035 score @ 24wk
NCT02634307 · Phase 3 · monotherapy
-0.006 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.026 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.037 score @ 48wk
NCT02634307 · Phase 3 · monotherapy
-0.01 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.03 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.036 score @ 72wk
NCT02634307 · Phase 3 · monotherapy
-0.009 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.042 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
-0.057 score @ 96wk
NCT02634307 · Phase 3 · monotherapy
Time to Confirmed Disability Progression 8.21 months
time to event · months
No placebo or comparator arm
NCT02634307 · Phase 3 · monotherapy · converted to months from 250 days as posted
show 2 more results
8.36 months*
NCT02634307 · Phase 3 · monotherapy · converted to months from 254.5 days as posted
5.78 months*
NCT02634307 · Phase 3 · monotherapy · converted to months from 176 days as posted
NEDA 24.8% (n=487) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NEDA-3
NCT02634307 · Phase 3 · monotherapy
show 2 more results
34.6% (n=185) @ 96wk
NEDA-3
NCT02634307 · Phase 3 · monotherapy
28.6% (n=185) @ 96wk
NEDA-3
NCT02634307 · Phase 3 · monotherapy
NEDA-4 14.3% (n=487) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NEDA-4
NCT02634307 · Phase 3 · monotherapy
show 2 more results
15.2% (n=185) @ 96wk
NEDA-4
NCT02634307 · Phase 3 · monotherapy
11.9% (n=185) @ 96wk
NEDA-4
NCT02634307 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dimethyl fumarate (Tecfidera)'s landscape · Diroximel fumarate's landscape